Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a

Antiviral Therapy

Volumn 14, Issue 8, 2009, Pages 1183-1188

  Moucari, Rami ^a,b,c   Martinot Peignoux, Michelle ^a,b,c   Mackiewicz, Vincent ^a   Boyer, Nathalie ^a,b,c   Ripault, Marie Pierre ^a,b,c   Castelnau, Corinne ^a,b,c   Leclere, Laurence ^a,b,c   Dauvergne, Agnes ^a   Valla, Dominique ^a,b,c   Vidaud, Michel ^a   Nicolas Chanoine, Marie Hélène ^b   Marcellin, Patrick ^a,b,c  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; VIRUS DNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; KINETICS; MALE; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 73449089431     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1458     Document Type: Article

References (13)

1. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004; 24 Suppl 1:3-10.
2. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008; 13:211-220.
3. Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50:1084-1092.
4. Marcellin P, Bonino F, Lau GKK, et al. Sustained responses in patients with HBeAg-negative chronic hepatitis B 3 years after treatment with to peginterferon alfa-2a. Gastroenterology 2009; 136:2169-2179.
5. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49:1151-1157.
6. Bonino F, Marcellin P, Lau GKK, et al. Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56:699-705.
7. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
8. Han SB, Chang T, Chao Y, et al. Five years of continuous entecavir for nucleoside-naive HBeAg(+) chronic hepatitis B: results from study ETV-901. Hepatology 2008; 48 Suppl 1:705A.
9. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49:1141-1150.
10. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with peg-interferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101:297-303.
11. Liu CJ, Chen PJ, Wang HY, Lai MY, Kao JH, Chen DS. Lack of interferon sensitivity-determining region in the genome of hepatitis B virus genotype Ba. Antivir Ther 2004; 9:895-903.
12. Hou J, Schilling R, Janssen HL, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol 2007; 79:1055-1063.
13. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123:1848-1856.